OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Neuro-Oncology is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Response to correspondence on an exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma	63
Factors influencing timely diagnosis in neurolymphomatosis	50
Variables associated with 90-day readmission following craniotomy for tumor in the pediatric population	45
Preoperative meningioma vascularity index is associated with significantly increased intraoperative blood loss and greater risk of subtotal resection	42
Relationship between apparent diffusion coefficient and survival as a function of distance from gross tumor volume on radiation planning MRI in newly diagnosed glioblastoma	41
Letter: Exploring cell-free DNA as a biomarker for assessing tumor burden in metastatic spine disease	39
Harnessing imaging biomarkers for glioblastoma metastasis diagnosis: a correspondence	39
Prognostic factors among patients with brain metastases from cancer of unknown primary site	39
Neuropsychological functioning during chemotherapy with temozolomide in high-grade glioma patients: a retrospective single centre study	38
Different clinical and cytogenetic features of primary skull base meningiomas and non-skull base meningiomas	36
Predictors of brain metastases in patients with oligometastatic solid tumours treated with stereotactic body radiation therapy	36
Congress of Neurological Surgeons systematic review and evidence‑based guidelines on the management of recurrent diffuse low-grade glioma: update	34
Differentiating radiation necrosis from tumor recurrence: a systematic review and diagnostic meta-analysis comparing imaging modalities	32
Fractionated stereotactic radiotherapy in craniopharyngiomas: A systematic review and single arm meta-analysis	32
Complete resolution of peritumoral FLAIR hyperintensity is infrequent in surgically treated patients with intracranial meningiomas	31
Whole Body-MRI assessment of peripheral lesions in patients with NF2-related schwannomatosis on systemic bevacizumab	30
Accelerated hyper-versus normofractionated radiochemotherapy with temozolomide in patients with glioblastoma: a multicenter retrospective analysis	29
Distinct size and spatial distribution patterns of ALK-inhibitor-naïve versus ALK-inhibitor exposed ALK-positive NSCLC brain metastases	29
The 5-factor modified frailty index as a prognostic factor for stereotactic radiosurgery in meningioma management	28
Immune-related aseptic meningitis and strategies to manage immune checkpoint inhibitor therapy: a systematic review	28
The trial effect in patients with glioblastoma: effect of clinical trial enrollment on overall survival	27
Elevated baseline C-reactive protein levels predict poor progression-free survival in sporadic vestibular schwannoma	27
Focused versus conventional radiotherapy in spinal oncology: is there any difference in fusion rates and pseudoarthrosis?	27
Improved survival and intracranial tumor control of EGFR-mutated NSCLC patients with newly developed brain metastases following stereotactic radiosurgery and EGFR-TKI: a large retrospective cohort stu	27
Development of a recursive partitioning analysis for prediction of radiation necrosis following single-fraction stereotactic radiosurgery for intact brain metastases	26

Efficacy of endoscopic management of primary central nervous system lymphoma: a multicentric study and literature review	26
MR susceptibility imaging for detection of tumor-associated macrophages in glioblastoma	26
Two is better than one: longitudinal detection and volumetric evaluation of brain metastases after Stereotactic Radiosurgery with a deep learning pipeline	26
A practical guide to neuro-oncology fellowship	26
Spatial invasion patterns of temporal lobe glioblastoma after complete resection of contrast-enhancing tumor	26